A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Inclusion Criteria:

• Must understand and voluntarily sign an informed consent form.

• Must be ≥18 years of age at the time of signing the informed consent form.

• Must be able to adhere to the study visit schedule and other protocol requirements.

• Must be diagnosed with multiple myeloma that is progressing after at least 2 cycles ofanti-myeloma treatment or that has relapsed with progressive disease after treatment.

• Subjects may have been previously treated with thalidomide and/or radiation therapy.In addition, radiation therapy initiated prior to or at baseline (Day 1) may be givenconcurrently with study therapy, provided that all other eligibility criteria aresatisfied.

• Subjects must discontinue all anti-myeloma drug or non-drug therapy prior to the firstdose of study drug with the exception of radiation therapy initiated prior to or atbaseline (Day 1).

• Measurable levels of myeloma paraprotein in serum (>0.5 g/dL) or urine (>0.2 gexcreted in a 24-hour collection sample).

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.

• Females of childbearing potential (FCBP) must agree to use two reliable forms ofcontraception simultaneously or to practice complete abstinence from heterosexualintercourse during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for atleast 28 days after discontinuation from the study.

Exclusion Criteria:

• The presence of any of the following will exclude a subject from study enrollment:

• Any serious medical condition, laboratory abnormality, or psychiatric illness thatwould prevent the subject from signing the informed consent form.

• Pregnant or lactating females.

• Any condition, including the presence of laboratory abnormalities, which places thesubject at unacceptable risk if he/she were to participate in the study or confoundsthe ability to interpret data from the study.

• Any of the following laboratory abnormalities:

• Absolute neutrophil count (ANC) <1,000 cells/mm^3 (1.0 x 10^9/L)

• Platelet count <75,000/mm^3 (75 x 109/L) for subjects in whom <50% of the bonemarrow nucleated cells are plasma cells.

• Platelet count <30,000/mm^3 (30x10^9/L) for subjects in whom ≥50% of bone marrownucleated cells are plasma cells.

• Serum creatinine >2.5 mg/dL (221 µmol/L)

• Serum SGOT/AST or SGPT/ALT >3.0 x upper limit of normal (ULN)

• Serum total bilirubin >2.0 mg/dL (34 µmol/L)

• Prior history of malignancies other than multiple myeloma (except for basal cell orsquamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast)unless the subject has been free of the disease for ≥1 year.

• Prior history of stroke and/or thromboembolic event

• Known hypersensitivity to thalidomide or dexamethasone.

• Prior history of uncontrollable side effects to dexamethasone therapy.

• The development of a desquamating rash while taking thalidomide.

• Neuropathy ≥ Grade 2.